{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:37.978775Z",
     "start_time": "2019-03-16T18:28:34.342516Z"
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Populating the interactive namespace from numpy and matplotlib\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "%pylab inline"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Drugs table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:38.905027Z",
     "start_time": "2019-03-16T18:28:37.983073Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(1203, 36)"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drugs = pd.read_excel('bcdrugs.xlsx')\n",
    "drugs.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Drugs columns = 'Drug ID', 'Drug Name', 'CAS Number', 'Chemical Name',\n",
    "       'New Molecular Entity', 'Drug Interactions', 'Comparative Efficacy',\n",
    "       'Highest Development Phase', 'Indication', 'Molecular Formula',\n",
    "       'Mechanism Of Action', 'Organisation',\n",
    "       'Pharmacodynamic Characteristics', 'Route Of Administration',\n",
    "       'Route Of Elimination', 'Pharmacokinetic Characteristics',\n",
    "       'Adverse Events', 'Therapeutic Class (EphMRA)',\n",
    "       'Therapeutic Class (WHO)', 'Synonyms/Brand Names',\n",
    "       'Antimicrobial Activity', 'Immunogenicity',\n",
    "       'Last Significant Update Date', 'Therapeutic Area',\n",
    "       'Orphan Designation', 'License Availability', 'Brands', 'On Fastrack',\n",
    "       'Fastrack country', 'On PRIME', 'PRIME country', 'Biomarkers-Inclusion',\n",
    "       'Biomarkers-Exclusion', 'Biomarkers-Outcome Measure',\n",
    "       'Biomarkers-Safety', 'Biomarkers-not specified'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:38.926587Z",
     "start_time": "2019-03-16T18:28:38.908132Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Marketed                                     175\n",
       "Preclinical                                  167\n",
       "Phase II                                     149\n",
       "No development reported (Preclinical)         87\n",
       "Phase III                                     84\n",
       "Discontinued (II)                             84\n",
       "Phase I                                       65\n",
       "Discontinued (Preclinical)                    60\n",
       "Discontinued (III)                            46\n",
       "Phase I/II                                    44\n",
       "Research                                      35\n",
       "Discontinued (I)                              25\n",
       "No development reported (I)                   21\n",
       "No development reported (Research)            21\n",
       "No development reported (II)                  20\n",
       "Registered                                    15\n",
       "Phase II/III                                  14\n",
       "Discontinued (I/II)                           11\n",
       "Preregistration                               10\n",
       "No development reported (Clinical)            10\n",
       "Discontinued (Preregistration)                10\n",
       "No development reported (I/II)                 7\n",
       "Clinical Phase Unknown                         7\n",
       "Suspended (I)                                  5\n",
       "Suspended (II)                                 5\n",
       "Discontinued (Clinical)                        4\n",
       "No development reported (III)                  3\n",
       "Suspended (III)                                3\n",
       "No development reported                        2\n",
       "Discontinued (Registered)                      2\n",
       "Discontinued (II/III)                          2\n",
       "No development reported (Preregistration)      2\n",
       "Phase Unknown                                  2\n",
       "Preregistration Submission Withdrawal          1\n",
       "Discontinued                                   1\n",
       "No development reported (Registered)           1\n",
       "Market Withdrawal                              1\n",
       "Discontinued (Research)                        1\n",
       "Phase 0                                        1\n",
       "Name: Highest Development Phase, dtype: int64"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drugs['Highest Development Phase'].value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Trials table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:42.821275Z",
     "start_time": "2019-03-16T18:28:38.934320Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(4529, 41)"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials = pd.read_excel('bcdrugsct.xlsx')\n",
    "trials.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:42.847795Z",
     "start_time": "2019-03-16T18:28:42.825167Z"
    }
   },
   "outputs": [],
   "source": [
    "cols = ['Trial ID','Mechanism of action', 'Drug class (therapeutic effect)', 'Drug class (chemical)', \\\n",
    "        'Indication', 'Organisations', 'Trial Design', 'Location', 'Phase of Trial', 'Subject Age',\\\n",
    "        'Planned Subject Number', 'Trial Centre Details', 'Lead Centre', 'Trial Initiation date', \\\n",
    "        'Trial End date', 'Trial Status', 'Trial History', 'Diseases treated', 'Primary Drugs']\n",
    "smaller_trials = trials[cols]\n",
    "date_cols = ['Phase of Trial','Trial Initiation date', 'Trial End date', 'trial_start','trial_end']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:58.891263Z",
     "start_time": "2019-03-16T18:28:58.790556Z"
    }
   },
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "Cannot set a frame with no defined index and a value that cannot be converted to a Series",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[0;32m/anaconda3/lib/python3.7/site-packages/pandas/core/frame.py\u001b[0m in \u001b[0;36m_ensure_valid_index\u001b[0;34m(self, value)\u001b[0m\n\u001b[1;32m   3172\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3173\u001b[0;31m                 \u001b[0mvalue\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mSeries\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3174\u001b[0m             \u001b[0;32mexcept\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.7/site-packages/pandas/core/series.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, data, index, dtype, name, copy, fastpath)\u001b[0m\n\u001b[1;32m    276\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 277\u001b[0;31m                 \u001b[0mdata\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mSingleBlockManager\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdata\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mindex\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfastpath\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mTrue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    278\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.7/site-packages/pandas/core/internals.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, block, axis, do_integrity_check, fastpath)\u001b[0m\n\u001b[1;32m   4676\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mblock\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mBlock\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 4677\u001b[0;31m             \u001b[0mblock\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mmake_block\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mblock\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mplacement\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mslice\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0maxis\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mndim\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   4678\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.7/site-packages/pandas/core/internals.py\u001b[0m in \u001b[0;36mmake_block\u001b[0;34m(values, placement, klass, ndim, dtype, fastpath)\u001b[0m\n\u001b[1;32m   3204\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3205\u001b[0;31m     \u001b[0;32mreturn\u001b[0m \u001b[0mklass\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mndim\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mndim\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mplacement\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mplacement\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3206\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.7/site-packages/pandas/core/internals.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, values, placement, ndim)\u001b[0m\n\u001b[1;32m   2302\u001b[0m         super(ObjectBlock, self).__init__(values, ndim=ndim,\n\u001b[0;32m-> 2303\u001b[0;31m                                           placement=placement)\n\u001b[0m\u001b[1;32m   2304\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.7/site-packages/pandas/core/internals.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, values, placement, ndim)\u001b[0m\n\u001b[1;32m    124\u001b[0m                 \u001b[0;34m'Wrong number of items passed {val}, placement implies '\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 125\u001b[0;31m                 '{mgr}'.format(val=len(self.values), mgr=len(self.mgr_locs)))\n\u001b[0m\u001b[1;32m    126\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mValueError\u001b[0m: Wrong number of items passed 41, placement implies 0",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-7-36b230eeff8b>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     35\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0;34mf'min is {t_phase_1_min} and max is {t_phase_1_max}'\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     36\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 37\u001b[0;31m \u001b[0mphase_1\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'Xentuzumab'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     38\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     39\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m<ipython-input-7-36b230eeff8b>\u001b[0m in \u001b[0;36mphase_1\u001b[0;34m(drug_name)\u001b[0m\n\u001b[1;32m     27\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0mpd\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mto_datetime\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdate_str\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     28\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 29\u001b[0;31m     \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'trial_start'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mstart_to_datetime\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0maxis\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     30\u001b[0m     \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'trial_end'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mend_to_datetime\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0maxis\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     31\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.7/site-packages/pandas/core/frame.py\u001b[0m in \u001b[0;36m__setitem__\u001b[0;34m(self, key, value)\u001b[0m\n\u001b[1;32m   3117\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3118\u001b[0m             \u001b[0;31m# set column\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3119\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_set_item\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3120\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3121\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_setitem_slice\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkey\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.7/site-packages/pandas/core/frame.py\u001b[0m in \u001b[0;36m_set_item\u001b[0;34m(self, key, value)\u001b[0m\n\u001b[1;32m   3191\u001b[0m         \"\"\"\n\u001b[1;32m   3192\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3193\u001b[0;31m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_ensure_valid_index\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3194\u001b[0m         \u001b[0mvalue\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sanitize_column\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3195\u001b[0m         \u001b[0mNDFrame\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_set_item\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkey\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.7/site-packages/pandas/core/frame.py\u001b[0m in \u001b[0;36m_ensure_valid_index\u001b[0;34m(self, value)\u001b[0m\n\u001b[1;32m   3173\u001b[0m                 \u001b[0mvalue\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mSeries\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3174\u001b[0m             \u001b[0;32mexcept\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3175\u001b[0;31m                 raise ValueError('Cannot set a frame with no defined index '\n\u001b[0m\u001b[1;32m   3176\u001b[0m                                  \u001b[0;34m'and a value that cannot be converted to a '\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3177\u001b[0m                                  'Series')\n",
      "\u001b[0;31mValueError\u001b[0m: Cannot set a frame with no defined index and a value that cannot be converted to a Series"
     ]
    }
   ],
   "source": [
    "\n",
    "def phase_1(drug_name):\n",
    "    '''\n",
    "    take earliest Phase I date and latest Phase II\n",
    "    '''\n",
    "    tucatinib_trials = trials[trials['Primary Drugs']==drug_name]\n",
    "    trial_phases = ['Phase I', 'Phase II', 'Phase III']\n",
    "    cleaned_tucatinib_trials = tucatinib_trials[tucatinib_trials['Phase of Trial'].isin(trial_phases)]\n",
    "    phase_dummies = pd.get_dummies(cleaned_tucatinib_trials['Phase of Trial'])\n",
    "    cleaned_tucatinib_trials_dummies = cleaned_tucatinib_trials.join(phase_dummies)\n",
    "    #cleaned_tucatinib_trials_dummies[['Trial Initiation date', 'Trial End date']]\n",
    "    df = cleaned_tucatinib_trials.join(phase_dummies)\n",
    "\n",
    "    #not DRY as the answers to make multiargument apply functions involved more complicated things than I wanted.\n",
    "    def start_to_datetime(x):\n",
    "        date_str = re.findall('[\\d\\s\\w]*', x['Trial Initiation date'])[0].strip()\n",
    "        if date_str == '':\n",
    "            return False\n",
    "        else:\n",
    "            return pd.to_datetime(date_str)\n",
    "\n",
    "    def end_to_datetime(x):\n",
    "        date_str = re.findall('[\\d\\s\\w]*', x['Trial End date'])[0].strip()\n",
    "        if date_str == '':\n",
    "            return False\n",
    "        else:\n",
    "            return pd.to_datetime(date_str)\n",
    "\n",
    "    df['trial_start'] = df.apply(start_to_datetime, axis=1)\n",
    "    df['trial_end'] = df.apply(end_to_datetime, axis=1)\n",
    "\n",
    "    t_phase_1_min = min(list(df[(df['trial_start']!=False) & (df['Phase of Trial']=='Phase I')]['trial_start'].values))\n",
    "    t_phase_1_max = max(list(df[(df['trial_start']!=False) & (df['Phase of Trial']=='Phase I')]['trial_start'].values))\n",
    "\n",
    "    return f'min is {t_phase_1_min} and max is {t_phase_1_max}'\n",
    "\n",
    "phase_1('Xentuzumab')\n",
    "\n",
    "\n",
    "# df['split_start_date'] = df['Trial Initiation date'].apply(lambda x: x.split(' '))\n",
    "# df['split_end_date'] = df['Trial End date'].apply(lambda x: x.split(' '))\n",
    "# df2 = df[df['split_start_date'].apply(lambda x: len(x[:3]))==3]\n",
    "# df3 = df2[df2['split_end_date'].apply(lambda x: len(x[:3]))==3]\n",
    "# df3[date_cols]\n",
    "#df3.apply(lambda x: ' '.join(x['split_start_date']))\n",
    "# in_progress_trials = trials[trials['split_start_date'].apply(lambda x: len(x[:3]))==3]\n",
    "# planned_trials = trials[trials['split_start_date'].apply(lambda x: len(x[:3]))==2]\n",
    "# # one_split = trials['split_end_date'].values[0]\n",
    "# # pd.to_datetime(' '.join(one_split[:3]))\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:59.014876Z",
     "start_time": "2019-03-16T18:28:59.000136Z"
    }
   },
   "outputs": [],
   "source": [
    "phase_two = smaller_trials[smaller_trials['Phase of Trial'] == 'Phase II']\n",
    "phase_three = smaller_trials[smaller_trials['Phase of Trial'] == 'Phase III']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:59.179851Z",
     "start_time": "2019-03-16T18:28:59.173267Z"
    }
   },
   "outputs": [],
   "source": [
    "unique_drugs =list(smaller_trials['Primary Drugs'].unique())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:59.417251Z",
     "start_time": "2019-03-16T18:28:59.351739Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Trial ID</th>\n",
       "      <th>Trial Title</th>\n",
       "      <th>Mechanism of action</th>\n",
       "      <th>Drug class (therapeutic effect)</th>\n",
       "      <th>Drug class (chemical)</th>\n",
       "      <th>Drug class (biological)</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Organisations</th>\n",
       "      <th>Trial Design</th>\n",
       "      <th>Trial Endpoints</th>\n",
       "      <th>...</th>\n",
       "      <th>Trial End date</th>\n",
       "      <th>Trial Status</th>\n",
       "      <th>Trial History</th>\n",
       "      <th>Diseases treated</th>\n",
       "      <th>Biomarkers-Inclusion</th>\n",
       "      <th>Biomarkers-Exclusion</th>\n",
       "      <th>Biomarkers-Outcome Measure</th>\n",
       "      <th>Biomarkers-Safety</th>\n",
       "      <th>Biomarkers-not specified</th>\n",
       "      <th>Primary Drugs</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>700240183</td>\n",
       "      <td>A Phase 1b, Open-label Study to Assess the Saf...</td>\n",
       "      <td>Antibody-dependent cell cytotoxicity, Antimeta...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer, Male breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Incidence of adverse events\\ntime_frame: Up to...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Jul 2019 (planned)</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>700257487</td>\n",
       "      <td>Phase 2 Randomized, Double-Blinded, Controlled...</td>\n",
       "      <td>Antibody-dependent cell cytotoxicity, Antibody...</td>\n",
       "      <td>Antineoplastics, Antineoplastics, Antineoplast...</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Monoclonal antibodies, Monoclonal antibodies</td>\n",
       "      <td>Advanced breast cancer, Carcinoma, Male breast...</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>double-blind, multicentre, parallel, prospecti...</td>\n",
       "      <td>Progression-free survival (PFS) per RECIST 1.1...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Jul 2021 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>700304216</td>\n",
       "      <td>A Phase 1, Open-Label, Fixed-Sequence, Drug-Dr...</td>\n",
       "      <td>AMP activated protein kinase stimulants, Emiss...</td>\n",
       "      <td>Antineoplastics, Antihyperglycaemics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>open, prospective</td>\n",
       "      <td>Maximum observed plasma concentration (Cmax) o...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Mar 2019 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-03-06|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>478</th>\n",
       "      <td>700302859</td>\n",
       "      <td>A Phase 1, Randomized, Partially Double-Blind,...</td>\n",
       "      <td>DNA gyrase inhibitors, ERBB 2 receptor antagon...</td>\n",
       "      <td>Antineoplastics, Antibacterials</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>crossover, double-blind, prospective, randomised</td>\n",
       "      <td>Placebo-corrected change-from-baseline in QTcF...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Mar 2019 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-02-03|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>481</th>\n",
       "      <td>700238859</td>\n",
       "      <td>A Phase 1b, Open-label Study to Assess the Saf...</td>\n",
       "      <td>Apoptosis stimulants, ERBB 2 receptor antagoni...</td>\n",
       "      <td>Antineoplastics, Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>Immunoconjugates, Immunotoxins, Monoclonal ant...</td>\n",
       "      <td>Advanced breast cancer, Male breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>multicentre, open, prospective</td>\n",
       "      <td>Incidence and severity of adverse events\\nsafe...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Jul 2019 (planned)</td>\n",
       "      <td>Active, no longer recruiting</td>\n",
       "      <td>2019-02-01|Other trial event|Last checked agai...</td>\n",
       "      <td>Advanced breast cancer|treatment|stage IV; Mal...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>489</th>\n",
       "      <td>700301177</td>\n",
       "      <td>An Open-label, Non-randomized, Single-dose, Pa...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Maximum observed concentration\\ndescription: P...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 May 2019 (planned)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>2019-02-01|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>570</th>\n",
       "      <td>700301239</td>\n",
       "      <td>A Phase 1, Open-Label, Fixed-sequence, 5-part,...</td>\n",
       "      <td>14-alpha demethylase inhibitors, Angiogenesis ...</td>\n",
       "      <td>Antineoplastics, Antihyperlipidaemics, Antifun...</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Seattle Genetics, Seattle Genetics</td>\n",
       "      <td>multicentre, open, parallel, prospective</td>\n",
       "      <td>Area under the concentration-time curve (AUC) ...</td>\n",
       "      <td>...</td>\n",
       "      <td>28 Dec 2018 (actual)</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2019-01-22|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>915</th>\n",
       "      <td>700302217</td>\n",
       "      <td>A Phase 1, Open-label Study of the Absorption,...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer, Colorectal cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>open, prospective</td>\n",
       "      <td>Area under the concentration-time curve (AUC) ...</td>\n",
       "      <td>...</td>\n",
       "      <td>30 Jan 2018 (actual)</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2018-12-05|New trial record|New trial record</td>\n",
       "      <td>Breast cancer|treatment|; Colorectal cancer|tr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1507</th>\n",
       "      <td>700026682</td>\n",
       "      <td>A Study of ARRY-380 in Patients With Advanced ...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Advanced breast cancer, Bladder cancer, Colore...</td>\n",
       "      <td>Array BioPharma, Array BioPharma</td>\n",
       "      <td>multicentre, open, prospective</td>\n",
       "      <td>Characterize the safety profile of the study d...</td>\n",
       "      <td>...</td>\n",
       "      <td>01 Mar 2013 (actual)</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2018-08-31|Biomarker Update|Biomarkers informa...</td>\n",
       "      <td>Advanced breast cancer|treatment|second-line o...</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>HER2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1760</th>\n",
       "      <td>700292929</td>\n",
       "      <td>Expanded Access Use of Tucatinib for HER2+ Met...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Suspended</td>\n",
       "      <td>2018-04-05|Other trial event|Last checked agai...</td>\n",
       "      <td>Breast cancer|treatment|second-line or greater...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1812</th>\n",
       "      <td>700264999</td>\n",
       "      <td>Phase 3 study of tucatinib (ONT-380) in combin...</td>\n",
       "      <td>Apoptosis stimulants, ERBB 2 receptor antagoni...</td>\n",
       "      <td>Antineoplastics, Antineoplastics</td>\n",
       "      <td>Drug conjugates, Macrolides, Maytansinoids, 2 ...</td>\n",
       "      <td>Immunoconjugates, Immunotoxins, Monoclonal ant...</td>\n",
       "      <td>Breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics...</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Planning</td>\n",
       "      <td>2018-03-09|Other trial event|According to a Se...</td>\n",
       "      <td>Breast cancer|treatment|stage IV</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1814</th>\n",
       "      <td>700265020</td>\n",
       "      <td>A phase 2 study of tucatinib (ONT-380) in comb...</td>\n",
       "      <td>Apoptosis stimulants, ERBB 2 receptor antagoni...</td>\n",
       "      <td>Antineoplastics, Antineoplastics</td>\n",
       "      <td>Drug conjugates, Macrolides, Maytansinoids, 2 ...</td>\n",
       "      <td>Immunoconjugates, Immunotoxins, Monoclonal ant...</td>\n",
       "      <td>Breast cancer</td>\n",
       "      <td>Cascadian Therapeutics, Seattle Genetics</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Planning</td>\n",
       "      <td>2018-03-09|Other trial event|According to a Se...</td>\n",
       "      <td>Breast cancer|treatment|</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3880</th>\n",
       "      <td>700235510</td>\n",
       "      <td>Proof-of-concept trial of ARRY-380 in patients...</td>\n",
       "      <td>ERBB 2 receptor antagonists</td>\n",
       "      <td>Antineoplastics</td>\n",
       "      <td>2 ring heterocyclic compounds, Diamines, Furan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Advanced breast cancer, Brain metastases</td>\n",
       "      <td>Cascadian Therapeutics, Cascadian Therapeutics</td>\n",
       "      <td>prospective</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>(planned)</td>\n",
       "      <td>Planning</td>\n",
       "      <td>2013-08-09|New trial record|New trial record</td>\n",
       "      <td>Advanced breast cancer|treatment|; Brain metas...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tucatinib</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>13 rows Ã— 41 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       Trial ID                                        Trial Title  \\\n",
       "1     700240183  A Phase 1b, Open-label Study to Assess the Saf...   \n",
       "10    700257487  Phase 2 Randomized, Double-Blinded, Controlled...   \n",
       "16    700304216  A Phase 1, Open-Label, Fixed-Sequence, Drug-Dr...   \n",
       "478   700302859  A Phase 1, Randomized, Partially Double-Blind,...   \n",
       "481   700238859  A Phase 1b, Open-label Study to Assess the Saf...   \n",
       "489   700301177  An Open-label, Non-randomized, Single-dose, Pa...   \n",
       "570   700301239  A Phase 1, Open-Label, Fixed-sequence, 5-part,...   \n",
       "915   700302217  A Phase 1, Open-label Study of the Absorption,...   \n",
       "1507  700026682  A Study of ARRY-380 in Patients With Advanced ...   \n",
       "1760  700292929  Expanded Access Use of Tucatinib for HER2+ Met...   \n",
       "1812  700264999  Phase 3 study of tucatinib (ONT-380) in combin...   \n",
       "1814  700265020  A phase 2 study of tucatinib (ONT-380) in comb...   \n",
       "3880  700235510  Proof-of-concept trial of ARRY-380 in patients...   \n",
       "\n",
       "                                    Mechanism of action  \\\n",
       "1     Antibody-dependent cell cytotoxicity, Antimeta...   \n",
       "10    Antibody-dependent cell cytotoxicity, Antibody...   \n",
       "16    AMP activated protein kinase stimulants, Emiss...   \n",
       "478   DNA gyrase inhibitors, ERBB 2 receptor antagon...   \n",
       "481   Apoptosis stimulants, ERBB 2 receptor antagoni...   \n",
       "489                         ERBB 2 receptor antagonists   \n",
       "570   14-alpha demethylase inhibitors, Angiogenesis ...   \n",
       "915                         ERBB 2 receptor antagonists   \n",
       "1507                        ERBB 2 receptor antagonists   \n",
       "1760                        ERBB 2 receptor antagonists   \n",
       "1812  Apoptosis stimulants, ERBB 2 receptor antagoni...   \n",
       "1814  Apoptosis stimulants, ERBB 2 receptor antagoni...   \n",
       "3880                        ERBB 2 receptor antagonists   \n",
       "\n",
       "                        Drug class (therapeutic effect)  \\\n",
       "1     Antineoplastics, Antineoplastics, Antineoplastics   \n",
       "10    Antineoplastics, Antineoplastics, Antineoplast...   \n",
       "16                 Antineoplastics, Antihyperglycaemics   \n",
       "478                     Antineoplastics, Antibacterials   \n",
       "481                    Antineoplastics, Antineoplastics   \n",
       "489                                     Antineoplastics   \n",
       "570   Antineoplastics, Antihyperlipidaemics, Antifun...   \n",
       "915                                     Antineoplastics   \n",
       "1507                                    Antineoplastics   \n",
       "1760                                    Antineoplastics   \n",
       "1812                   Antineoplastics, Antineoplastics   \n",
       "1814                   Antineoplastics, Antineoplastics   \n",
       "3880                                    Antineoplastics   \n",
       "\n",
       "                                  Drug class (chemical)  \\\n",
       "1     2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "10    2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "16    2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "478   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "481   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "489   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "570   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "915   2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "1507  2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "1760  2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "1812  Drug conjugates, Macrolides, Maytansinoids, 2 ...   \n",
       "1814  Drug conjugates, Macrolides, Maytansinoids, 2 ...   \n",
       "3880  2 ring heterocyclic compounds, Diamines, Furan...   \n",
       "\n",
       "                                Drug class (biological)  \\\n",
       "1                                 Monoclonal antibodies   \n",
       "10         Monoclonal antibodies, Monoclonal antibodies   \n",
       "16                                                  NaN   \n",
       "478                                                 NaN   \n",
       "481   Immunoconjugates, Immunotoxins, Monoclonal ant...   \n",
       "489                                                 NaN   \n",
       "570                                                 NaN   \n",
       "915                                                 NaN   \n",
       "1507                                                NaN   \n",
       "1760                                                NaN   \n",
       "1812  Immunoconjugates, Immunotoxins, Monoclonal ant...   \n",
       "1814  Immunoconjugates, Immunotoxins, Monoclonal ant...   \n",
       "3880                                                NaN   \n",
       "\n",
       "                                             Indication  \\\n",
       "1            Advanced breast cancer, Male breast cancer   \n",
       "10    Advanced breast cancer, Carcinoma, Male breast...   \n",
       "16                     Breast cancer, Colorectal cancer   \n",
       "478                    Breast cancer, Colorectal cancer   \n",
       "481          Advanced breast cancer, Male breast cancer   \n",
       "489                    Breast cancer, Colorectal cancer   \n",
       "570                    Breast cancer, Colorectal cancer   \n",
       "915                    Breast cancer, Colorectal cancer   \n",
       "1507  Advanced breast cancer, Bladder cancer, Colore...   \n",
       "1760                                      Breast cancer   \n",
       "1812                                      Breast cancer   \n",
       "1814                                      Breast cancer   \n",
       "3880           Advanced breast cancer, Brain metastases   \n",
       "\n",
       "                                          Organisations  \\\n",
       "1     Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "10    Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "16                   Seattle Genetics, Seattle Genetics   \n",
       "478                  Seattle Genetics, Seattle Genetics   \n",
       "481   Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "489                  Seattle Genetics, Seattle Genetics   \n",
       "570                  Seattle Genetics, Seattle Genetics   \n",
       "915   Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "1507                   Array BioPharma, Array BioPharma   \n",
       "1760     Cascadian Therapeutics, Cascadian Therapeutics   \n",
       "1812  Cascadian Therapeutics, Cascadian Therapeutics...   \n",
       "1814           Cascadian Therapeutics, Seattle Genetics   \n",
       "3880     Cascadian Therapeutics, Cascadian Therapeutics   \n",
       "\n",
       "                                           Trial Design  \\\n",
       "1              multicentre, open, parallel, prospective   \n",
       "10    double-blind, multicentre, parallel, prospecti...   \n",
       "16                                    open, prospective   \n",
       "478    crossover, double-blind, prospective, randomised   \n",
       "481                      multicentre, open, prospective   \n",
       "489            multicentre, open, parallel, prospective   \n",
       "570            multicentre, open, parallel, prospective   \n",
       "915                                   open, prospective   \n",
       "1507                     multicentre, open, prospective   \n",
       "1760                                        prospective   \n",
       "1812                                        prospective   \n",
       "1814                                        prospective   \n",
       "3880                                        prospective   \n",
       "\n",
       "                                        Trial Endpoints      ...       \\\n",
       "1     Incidence of adverse events\\ntime_frame: Up to...      ...        \n",
       "10    Progression-free survival (PFS) per RECIST 1.1...      ...        \n",
       "16    Maximum observed plasma concentration (Cmax) o...      ...        \n",
       "478   Placebo-corrected change-from-baseline in QTcF...      ...        \n",
       "481   Incidence and severity of adverse events\\nsafe...      ...        \n",
       "489   Maximum observed concentration\\ndescription: P...      ...        \n",
       "570   Area under the concentration-time curve (AUC) ...      ...        \n",
       "915   Area under the concentration-time curve (AUC) ...      ...        \n",
       "1507  Characterize the safety profile of the study d...      ...        \n",
       "1760                                                NaN      ...        \n",
       "1812                                                NaN      ...        \n",
       "1814                                                NaN      ...        \n",
       "3880                                                NaN      ...        \n",
       "\n",
       "             Trial End date                  Trial Status  \\\n",
       "1     01 Jul 2019 (planned)  Active, no longer recruiting   \n",
       "10    01 Jul 2021 (planned)                    Recruiting   \n",
       "16    01 Mar 2019 (planned)                    Recruiting   \n",
       "478   01 Mar 2019 (planned)                    Recruiting   \n",
       "481   01 Jul 2019 (planned)  Active, no longer recruiting   \n",
       "489   01 May 2019 (planned)                    Recruiting   \n",
       "570    28 Dec 2018 (actual)                     Completed   \n",
       "915    30 Jan 2018 (actual)                     Completed   \n",
       "1507   01 Mar 2013 (actual)                     Completed   \n",
       "1760              (planned)                     Suspended   \n",
       "1812              (planned)                      Planning   \n",
       "1814              (planned)                      Planning   \n",
       "3880              (planned)                      Planning   \n",
       "\n",
       "                                          Trial History  \\\n",
       "1     2019-03-06|Other trial event|Last checked agai...   \n",
       "10    2019-03-06|Other trial event|Last checked agai...   \n",
       "16    2019-03-06|Other trial event|Last checked agai...   \n",
       "478   2019-02-03|Other trial event|Last checked agai...   \n",
       "481   2019-02-01|Other trial event|Last checked agai...   \n",
       "489   2019-02-01|Other trial event|Last checked agai...   \n",
       "570   2019-01-22|Other trial event|Last checked agai...   \n",
       "915        2018-12-05|New trial record|New trial record   \n",
       "1507  2018-08-31|Biomarker Update|Biomarkers informa...   \n",
       "1760  2018-04-05|Other trial event|Last checked agai...   \n",
       "1812  2018-03-09|Other trial event|According to a Se...   \n",
       "1814  2018-03-09|Other trial event|According to a Se...   \n",
       "3880       2013-08-09|New trial record|New trial record   \n",
       "\n",
       "                                       Diseases treated Biomarkers-Inclusion  \\\n",
       "1     Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "10    Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "16    Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "478   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "481   Advanced breast cancer|treatment|stage IV; Mal...                 HER2   \n",
       "489   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "570   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "915   Breast cancer|treatment|; Colorectal cancer|tr...                  NaN   \n",
       "1507  Advanced breast cancer|treatment|second-line o...                 HER2   \n",
       "1760  Breast cancer|treatment|second-line or greater...                  NaN   \n",
       "1812                   Breast cancer|treatment|stage IV                  NaN   \n",
       "1814                           Breast cancer|treatment|                  NaN   \n",
       "3880  Advanced breast cancer|treatment|; Brain metas...                  NaN   \n",
       "\n",
       "     Biomarkers-Exclusion  Biomarkers-Outcome Measure Biomarkers-Safety  \\\n",
       "1                    HER2                         NaN               NaN   \n",
       "10                   HER2                         NaN               NaN   \n",
       "16                    NaN                         NaN               NaN   \n",
       "478                   NaN                         NaN               NaN   \n",
       "481                  HER2                         NaN               NaN   \n",
       "489                   NaN                         NaN               NaN   \n",
       "570                   NaN                         NaN               NaN   \n",
       "915                   NaN                         NaN               NaN   \n",
       "1507                  NaN                        HER2               NaN   \n",
       "1760                  NaN                         NaN               NaN   \n",
       "1812                  NaN                         NaN               NaN   \n",
       "1814                  NaN                         NaN               NaN   \n",
       "3880                  NaN                         NaN               NaN   \n",
       "\n",
       "      Biomarkers-not specified Primary Drugs  \n",
       "1                          NaN     Tucatinib  \n",
       "10                         NaN     Tucatinib  \n",
       "16                         NaN     Tucatinib  \n",
       "478                        NaN     Tucatinib  \n",
       "481                        NaN     Tucatinib  \n",
       "489                        NaN     Tucatinib  \n",
       "570                        NaN     Tucatinib  \n",
       "915                        NaN     Tucatinib  \n",
       "1507                       NaN     Tucatinib  \n",
       "1760                       NaN     Tucatinib  \n",
       "1812                       NaN     Tucatinib  \n",
       "1814                       NaN     Tucatinib  \n",
       "3880                       NaN     Tucatinib  \n",
       "\n",
       "[13 rows x 41 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials[trials['Primary Drugs']=='Tucatinib']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2019-03-16T18:28:59.542994Z",
     "start_time": "2019-03-16T18:28:59.525658Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Date</th>\n",
       "      <th>Status</th>\n",
       "      <th>Notes</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2019-03-06</td>\n",
       "      <td>Other trial event</td>\n",
       "      <td>Last checked against ClinicalTrials.gov record.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2019-01-25</td>\n",
       "      <td>Other trial event</td>\n",
       "      <td>Last checked against the European Clinical Tri...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2018-12-26</td>\n",
       "      <td>Other trial event</td>\n",
       "      <td>New source identified and integrated (European...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2018-12-19</td>\n",
       "      <td>Status change - recruiting</td>\n",
       "      <td>Status changed from not yet recruiting to recr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2018-11-06</td>\n",
       "      <td>New trial record</td>\n",
       "      <td>New trial record</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          Date                      Status  \\\n",
       "0   2019-03-06           Other trial event   \n",
       "1   2019-01-25           Other trial event   \n",
       "2   2018-12-26           Other trial event   \n",
       "3   2018-12-19  Status change - recruiting   \n",
       "4   2018-11-06            New trial record   \n",
       "\n",
       "                                               Notes  \n",
       "0    Last checked against ClinicalTrials.gov record.  \n",
       "1  Last checked against the European Clinical Tri...  \n",
       "2  New source identified and integrated (European...  \n",
       "3  Status changed from not yet recruiting to recr...  \n",
       "4                                   New trial record  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def trial_history_to_table(th):\n",
    "    rows = str.split(th, ';')\n",
    "    #columns_trial_1 = [str.split(i, '|') for i in rows_trial_1]\n",
    "    table = [str.split(row, '|') for row in rows]\n",
    "    return pd.DataFrame(table,columns=['Date','Status','Notes'])\n",
    "\n",
    "trial_history_to_table(phase_three['Trial History'].values[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
